ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Phase 2 Trial of TD-6424 Versus Standard Therapy for Complicated Gram Positive Infections of the Skin and Soft Tissue

This study has been completed.

Sponsored by: Theravance
Information provided by: Theravance
ClinicalTrials.gov Identifier: NCT00077675
  Purpose

Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 can control infections and whether the drug is safe to give to patients.


Condition Intervention Phase
Infections, Gram-Positive Bacterial
Drug: TD-6424
Phase II

Drug Information available for:   Telavancin   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   A Phase 2, Randomized, Double Blind, Multinational Trial of Intravenous TD 6424 Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections

Further study details as provided by Theravance:

Estimated Enrollment:   200
Study Start Date:   February 2004
Estimated Study Completion Date:   July 2004

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Patients must have a diagnosis of one of the following complicated skin and soft tissue infections and either a suspected or confirmed Gram positive organism

  • major abscess requiring surgical incision and drainage
  • infected burn
  • deep/extensive cellulitis
  • infected ulcer
  • wound infection
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00077675

Locations
United States, California
Paradise Valley Hospital    
      National City, California, United States, 91950

Sponsors and Collaborators
Theravance

Investigators
Principal Investigator:     G. Ralph Corey, MD     Duke University    
  More Information


Study ID Numbers:   I6424-202b, FAST 2
First Received:   February 10, 2004
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00077675
Health Authority:   United States: Food and Drug Administration

Keywords provided by Theravance:
Abscess  
Burns  
Cellulitis  
Ulcer  
Wound infections  

Study placed in the following topic categories:
Bacterial Infections
Burns
Gram-Positive Bacterial Infections
Cellulitis
Ulcer
Abscess
Wound Infection

Additional relevant MeSH terms:
Communicable Diseases
Infection

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers